![]() |
Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
More... |
| All times are GMT -7. The time now is 01:05 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021